Novel serum proteomic signatures in a non-human primate model of retinal injury

Jeffrey J. Dunmire,1 Rachida Bouhenni,1 Michael L. Hart,1 Bassam T. Wakim,2 Anthony M. Chomyk,1 Sarah E. Scott,1 Hiroshi Nakamura,1 Deepak P. Edward1

1Department of Ophthalmology, Summa Health System, Akron, OH; 2Department of Biochemistry, Medical College of Wisconsin, Milwaukee, WI

Purpose: To identify candidate protein biomarkers in sera indicative of acute retinal injury.

Methods: We used laser photocoagulation as a model of acute retinal injury in Rhesus macaques. In a paired-control study design, we collected serum from each animal (n=6) at 4 h, 1 day, and 3 days following a mock procedure and then again following retinal laser treatment that produced mild lesions. Samples were fractionated by isoelectric focusing, digested with trypsin, and analyzed by liquid chromatography/tandem mass spectrometry (LC-MS/MS). Spectral counting was used to determine relative protein abundances and identify proteins with statistically significant differences between control and treated sera.

Results: Mild retinal injury was confirmed by fundus photography and histological examination. The average number of total proteins detected by LC-MS/MS was 908±82 among samples from all three time points. Following statistical analysis and employing stringent filtering criteria, a total of 19 proteins were identified as being significantly more abundant in sera following laser-induced retinal injury, relative to control sera. Many of the proteins detected were unique to one time point. However, four proteins (phosphoglycerate kinase 1, keratin 18, Lewis alpha-3-fucosyltransferase, and ephrin receptor A2) showed differences that were significant at both 4 h and 1 day after laser treatment, followed by a decrease to baseline levels by day 3.

Conclusions: A serum biomarker response to mild retinal laser injury was demonstrated in a primate model. Among the proteins detected with highest significant differences, most are upregulated within 24 h, and their appearance in the serum is transient. It is conceivable that a panel of these proteins could provide a means for detecting the acute-phase response to retinal injury. Further investigation of these candidate biomarkers and their correlation to retinal damage is warranted.

Retinal proteins have been found in the serum of patients with conditions such as retinal detachment and diabetic retinopathy [1,2]. However, the identification of acute-phase biomarkers following retinal injury has not been described. We hypothesized that retinal injury by laser photocoagulation causes death and/or injury of photoreceptor and retinal pigment epithelium (RPE) cells, and that proteins that may be upregulated in response to the damage will be released from those, or adjacent, cells into the systemic circulation. Detection of such proteins in serum would allow the identification of candidate biomarkers. A panel of serum biomarkers could provide the basis for the development of a rapid and minimally invasive diagnostic test to detect acute retinal injury.

Laser-induced retinal damage for energy levels above the clinically detectable threshold has been well described. Retinal damage can be localized to deep or superficial layers, or might involve the entire retinal thickness, and has been extensively studied in animal models [3-5]. The mechanism of damage may be photothermal, photomechanical, photodisruptive, or photochemical [3]. Irrespective of the mechanism of damage, laser-tissue reaction leads to varying degrees of retinal neuronal and RPE cell damage or death [3-7]. It also leads to altered protein expression in the retina and disruption of the outer blood-retinal barrier [8-12]. It is conceivable that such events would lead to the leakage of proteins from the damaged photoreceptor/RPE cells and/or surrounding tissue through the underlying choroid and into the systemic circulation.

We sought to discover whether retinal injury could cause detectable leakage of proteins from the retina into the systemic circulation. Using a proteomics approach, we investigated whether detection of this acute-phase response process was possible over a three day course of time following injury. Liquid chromatography-tandem mass spectrometry (LC-MS/MS) analysis of complex biologic fluids is a highly sensitive method for observing qualitative and quantitative changes in protein content. Others have used LC-MS/MS-based proteomics as a means of detecting changes due to ocular disease [2,13] and the technique is used extensively for biomarker discovery. We used laser photocoagulation as a model of acute retinal damage in non-human primates.
followed by LC-MS/MS analysis to identify candidate protein biomarkers of retinal injury in serum.

**METHODS**

**Animals:** Seven female Rhesus macaques (Macaca mulatta), aged 2.5–3.5 years and weighing 3.0–4.5 kg, were used in this study. One animal was used for clinicopathologic correlation of laser injury and the remaining six were treated in a paired-control fashion. This study was conducted in accordance with the Association for Research in Vision and Ophthalmology’s Statement for the Use of Animals in Ophthalmic and Vision Research, and all experimental procedures were approved by the Institutional Animal Care and Use Committee at Northeastern Ohio Universities Colleges of Medicine and Pharmacy.

All animal procedures were performed under general anesthesia using 10 mg/kg ketamine and 0.075 mg/kg medetomidine, delivered intramuscularly. Upon completion of the procedures, 0.075 mg/kg atipamezole was administered as a reversing agent.

**Laser treatment:** We studied the serum biomarker response from retinal laser lesions ranging from mild to minimally visible lesions (MVLs). These retinal laser lesions appeared light gray to yellow in color immediately after the injury. It has been reported that these MVLs are not visible one week after laser exposure [3,5,7,14]. In one animal, we tested the ability to create MVLs that could be confirmed clinically and upon pathologic examination. Higher intensity laser burns were created as rows parallel to MVLs to aid in their identification upon clinical and pathologic examination. Fundus images were taken immediately following laser treatment. The eye was enucleated 24 h later, following euthanasia, for histological examination. The whole globe was fixed in 10% neutral buffered formalin, after which the retinal area containing lesions was carefully dissected and oriented to ensure both lesion types could be observed in the sections. The tissue was processed, embedded in paraffin, sectioned, and stained with hematoxylin and eosin. The experimental mock control and MVL procedures were then performed, as described below.

Each animal in this experiment served as its own control by undergoing a pre-treatment mock procedure. In this way, a baseline serum proteome was established for each animal, allowing any changes that may have occurred due to anesthesia, pupil dilation, or handling to be excluded. Following general anesthesia, the pupils were dilated with one drop each of tropicamide 1.0% (Bausch & Lomb, Tampa, FL) and phenylephrine HCl 2.5% (Alcon Laboratories, Fort Worth, TX), and one drop of proparacaine HCl 0.5% (Bausch & Lomb) was instilled as a local anesthetic. Eyes were examined by indirect ophthalmoscopy to rule out the presence of any retinal abnormality or other ocular disease. Three weeks following the control experiment, the animals were treated in a similar fashion, except that the right eye of each animal received laser treatment. Laser photoacogulation was performed with a frequency-doubled Nd: YAG 532 nm laser (OcuLight®GL; IRIDEX Corporation, Mountain View, CA). A total of 15 laser spots were applied to the retina superior to the optic nerve in the right eye. The laser settings were 500 μm spot diameter, 130–160 mW power intensity, and 0.1 s duration. These parameters consistently produced MVLs, as described previously.

**Sample collection:** Blood was collected by venipuncture, under general anesthesia, at 4 h, 1 day, and 3 days following both the mock procedure and the laser treatment. At each time point, approximately 5 ml of blood was drawn into collection tubes free of clot activator or other additives. After clotting at room temperature, the blood was centrifuged at 2,500× g for 10 min for serum separation. The collected serum was aliquoted to 1.5 ml tubes and stored at −80 °C until used for proteomic analysis.

**Sample preparation and mass spectrometry:** Knowing that protein concentrations in serum span a dynamic range of greater than 10 orders of magnitude [15,16] and that the 6–10 highest abundance serum proteins, which include albumin and globulin, account for greater than 90% of the total protein content [17,18], it is imperative to employ sample pre-fractionation before conducting mass spectrometry.

Albumin and globulin depletion is one way to reduce the complexity of serum, but may also lead to the depletion of potentially important protein targets and non-specific loss of low abundance proteins [19,20]. We elected to reduce the complexity of the serum by subjecting it to isoelectric focusing (IEF), which does not involve the removal of any proteins. This process, when compared to that without fractionation, led to the identification of six times the number of proteins using mass spectrometry. The use of IEF increased both the protein detection and identification rates to a degree that helped determine differences between the serum proteomes of control and treated animals.

The serum samples were pre-fractionated offline by liquid-phase IEF using a MicroRotofor™ (Bio-Rad Laboratories, Hercules, CA). Fifty microliters of each sample were focused in the range between pH 3–10, producing ten fractions that were each collected in a final volume of 200 μl. One hundred microliters from each serum fraction was pre-fractionated offline by liquid-phase IEF using a MicroRotofor™ (Bio-Rad Laboratories, Hercules, CA). Fifty microliters of each sample were focused in the range between pH 3–10, producing ten fractions that were each collected in a final volume of 200 μl. One hundred microliters from each serum fraction was aliquoted to 1.5 ml tubes and stored at −80 °C until used for proteomic analysis.

The serum samples were pre-fractionated offline by liquid-phase IEF using a MicroRotofor™ (Bio-Rad Laboratories, Hercules, CA). Fifty microliters of each sample were focused in the range between pH 3–10, producing ten fractions that were each collected in a final volume of 200 μl. One hundred microliters from each serum fraction was aliquoted to 1.5 ml tubes and stored at −80 °C until used for proteomic analysis.
from the gel pieces using 70% acetonitrile and 0.1% formic acid and then dried. Extracts were resuspended in 20 µl of 6 M guanidine-HCl, 5 mM potassium phosphate, and 1 mM DTT (pH 6.5), sonicated, and passed through a C18 ZipTip (Millipore, Billerica, MA) to extract the peptides, which were then dried. Prior to mass spectrometry, the dried peptide extracts were dissolved in 5 µl of 5% acetonitrile and 0.1% formic acid.

Peptides from each IEF fraction were analyzed once by automated nano-flow liquid chromatography tandem mass spectrometry (nano-flow LC-MS/MS) using an LTQ linear ion trap mass spectrometer (Thermo Fisher Scientific, Waltham, MA), coupled to a Surveyor HPLC system (Thermo Fisher Scientific) equipped with a Finnigan Micro AS autosampler, and interfaced with an Aquasil C18 PicoFrit 75 µm x 10 cm capillary column (New Objective, Woburn, MA). Peptide mixtures were first separated using the C18 reverse phase column (1 µl/min flow rate) in line with the mass spectrometer. Mobile phases consisted of 0.1% formic acid, 5% acetonitrile and 0.1% formic acid with 95% acetonitrile for solvents A and B, respectively. A linear gradient of 180 min was followed by 60 min equilibration in solvent A. Ions eluted from the column were electrospayed at a voltage of 1.75 kV. The LC-MS/MS cycle was 6 MS/MS scans per full MS scan. Dynamic exclusion enabled ±1.5 Da tolerance and 12 s exclusion duration.

Data analysis: Data generated from the raw spectra was searched against the Macaca mulatta subset of the UniProt database using the Sequest (V.12) program using a peptide mass tolerance of 2.5 Da, a fragment mass tolerance of “0” (which is effectively 1 Da), and monoisotopic masses.

Probability scores were calculated using Epitomize software [22,23] (Medical College of Wisconsin, Milwaukee, WI) and filtered at 0.85 and 0.60 for spectra and protein hits, respectively. Additionally, proteins identified by less than two unique peptides were eliminated and not considered for further statistical analysis. The protein hits from each set of ten IEF fractions for each sample were combined to represent the serum proteome of that specimen at the given time point. For each time point, the data results from all control and treated specimens were quantitatively compared using Visualize software [22,23] (Medical College of Wisconsin, Milwaukee, WI). A normalized p value for each protein was calculated using the G test as previously described [24]. These results were compiled into full and un-edited lists of proteins, before application of any further statistical criteria or filtering, and are available as supplemental data in Appendix 1, as described below in the Results section. Proteins with a normalized p value <0.05 were filtered to identify those detected either in treated samples only or with increased abundance in treated samples relative to the controls. The p values for this subset of data were adjusted according to the Holm-Sidak method of correction for multiple comparisons. Proteins with an adjusted p value <0.05 were considered significant and were retained. Proteins were eliminated from the list if the normalized scan count ratio did not represent at least a twofold increase in the treated group relative to the control. Additionally, proteins were filtered based on the frequency of detection; they were not included in the final list, despite their statistical significance, unless detected in at least 50% of the treated samples. The stringent statistical criteria and sorting methods were chosen to increase confidence in the final panel of candidate protein biomarkers. These choices helped to eliminate proteins that may have been specific only to individual animals or that may have been unrelated to the injury. Using our method, we minimized the rate of false identification and compiled a list of proteins that were both significantly present in each sample and significantly different between treatment groups. These methods for the comparative analysis of proteomic data sets have been successfully used in our laboratory, as described in a recent publication [25].

Protein lists for each time point were analyzed using Pathway Studio software (Ariadne, Rockville, MD). Using the human homolog gene identifiers, each protein was mapped to its associated gene ontology (GO) terms for both cellular components and biologic processes. The GO terms for each category were analyzed for enrichment. Terms common to the greatest number of proteins were used as the defining terms in each category.

RESULTS

Histopathological assessment of laser lesions: We confirmed the ability to create MVLs and mild type laser lesions, as demonstrated by fundus photography and histological examination. The pathologic changes associated with MVLs or severe type lesions were distinct and clearly identifiable in histological sections of treated retinas at 1 day after laser injury and when compared to normal retinas (Figure 1).

Protein identification and normalized scan count ratio: The total number of proteins detected by LC-MS/MS analysis were 818, 928, and 978 at the 4 h, 1 day, and 3 days time points, respectively. A comprehensive list of these proteins, identified by two or more non-redundant peptides, appears in Appendix 1 as supplemental data. These protein identifications served as the starting point for determining a final list of candidate biomarkers. For biomarkers of retinal injury, we chose to consider only those proteins that were either present in treated samples only or that showed increased abundance in treated samples relative to controls. In this case, the numbers of proteins considered for further statistical analysis and data filtering were 259, 189, and 353 for the 4 h, 1 day, and 3 days time points, respectively. The numbers of proteins that passed the additional statistical testing and met the final filtering criteria were 8, 12, and 3 for the 4 h, 1 day, and 3 days time points, respectively (Table 1). Based on their normalized scan count ratios, these proteins were identified...
as being considerably more abundant in sera following laser treatment.

Sera from the 4 h and 1 day time points had four proteins in common that were detected at significantly higher levels in treated samples compared to mock samples (Figure 2). These included phosphoglycerate kinase 1 (PGK1), keratin 18 (CK18), Lewis alpha-3-fucosyltransferase (FUT3), and ephrin receptor A2 (EPHA2). Additionally, these proteins showed high reproducibility for detection, having been identified in all six treated samples at both time points.

Six proteins were detected in either the 4 h or 1 day sera of treated animals only. In all cases, these proteins were also detected in both control and treated samples at the other time points, but the differences were not significant.

Gene ontology: The 19 proteins identified by spectral counting as potential biomarkers were classified according to gene ontology (GO) terms for both cellular components and...
| Time post-treatment | Macaca mulatta Uniprot ID | Human homolog gene ID | Protein description | Number samples w/ positive detection | Normalized scan count ratio (treated/control) | Holm-Sidak adjusted p-value |
|---------------------|---------------------------|-----------------------|---------------------|--------------------------------------|---------------------------------------------|----------------------------|
| 4h                  | Q8SPT9 3875              | Keratin 18 (CK18)     | 1                   | 6                                    | 16.8935                                    | 0.0000783                  |
| 4h                  | Q3YAQ9 5230              | Phosphoglycerate kinase 1 (PGK1) | 6                   | 6                                    | 2.7795                                    | 0.0019637                  |
| 4h                  | Q6XML5 721               | Complement factor 4 (C4) | 6                   | 6                                    | 2.2795                                    | 0.002356                   |
| 4h                  | Q8WNP0 2525              | Lewis alpha-3-fucosyltransferase (FUT3) | 6                   | 6                                    | 2.2169                                    | 0.003633                   |
| 4h                  | Q1HKZ4 1969              | Ephrin receptor A2 (EPHA2) | 0                   | 5                                    | -                                         | 0.003949                   |
| 4h                  | Q9TUC6 1138              | Nicotinic receptor alpha 5 subunit (CHRNA5) | 0                   | 4                                    | -                                         | 0.029670                   |
| 4h                  | B0IDR3 3106              | MHC class I antigen (HLA-B) | 0                   | 3                                    | -                                         | 0.001778                   |
| 1 Day               | Q3YAQ9 5230              | Phosphoglycerate kinase 1 (PGK1) | 2                   | 6                                    | 24.6994                                   | 5.42E-12                   |
| 1 Day               | Q8SPT9 3875              | Keratin 18 (CK18)     | 2                   | 6                                    | 22.7121                                   | 0.001E+00                  |
| 1 Day               | Q8WNP0 2525              | Lewis alpha-3-fucosyltransferase (FUT3) | 5                   | 6                                    | 15.3307                                   | 0.001E+00                  |
| 1 Day               | B1NL287 64816            | Cytochrome P450, 3A43 (CYP3A43) | 3                   | 6                                    | 6.2458                                    | 0.013228                   |
| 1 Day               | A9XMK3 146               | Alpha-1D adrenoreceptor (ADRA1D) | 4                   | 6                                    | 6.0684                                    | 0.001E+00                  |
| 1 Day               | P47899 153               | Beta-1 adrenergic receptor (ADRB1) | 3                   | 4                                    | 4.3532                                    | 0.000097                   |
| 1 Day               | Q5TM61 5514              | Protein phosphatase 1, regulatory subunit 10 (PPP1R10) | 5                   | 6                                    | 4.3240                                    | 4.47E-07                   |
| 1 Day               | B3Y660 51311             | Toll-like receptor 8 (TLR8) | 6                   | 6                                    | 3.2290                                    | 0.001E+00                  |
| 1 Day               | Q1HKZ4 1969              | Ephrin receptor A2 (EPHA2) | 6                   | 6                                    | 2.7874                                    | 0.000157                   |
| 1 Day               | Q8HYQ1 6352              | C-C motif chemokine 5 (CCL5) | 0                   | 6                                    | -                                         | 0.000258                   |
| 1 Day               | Q5YAN2 51185             | Cereblon (CRBN)       | 0                   | 6                                    | -                                         | 0.016533                   |
| 1 Day               | Q4GV53 793               | 28kDa calbindin 1 (CALB1) | 0                   | 6                                    | -                                         | 0.041927                   |
| 3 Days              | Q50KV9 5429              | Taste receptor type 2 (TAS2R5) | 3                   | 5                                    | 5.6981                                    | 0.002844                   |
| 3 Days              | B04K3P 148               | Alpha-1A adrenoreceptor (ADRA1A) | 4                   | 6                                    | 5.2097                                    | 0.011880                   |
| 3 Days              | Q91143 7297              | Tyrosine kinase-2 (TYK2) | 6                   | 6                                    | 2.2057                                    | 0.021489                   |
biologic processes (Table 2). Eight of the proteins were classified as being integral to the cell membrane, six of which have roles in signal transduction and two of which are involved in the immune response. Two proteins were classified as specific to organelle membranes (Golgi and endoplasmic reticulum). Five proteins were identified that localize in the cytoplasm, while three others localize in the extracellular region. Four of the proteins have association with the post-translational modification function and two play a role in the inflammatory response. One cytoplasmic protein, keratin 18, is an intermediate filament of the cytoskeleton and was classified in terms of its biologic process as having an association with the regulation of apoptosis.

DISCUSSION

In this study, we describe a panel of candidate protein biomarkers that appear to be considerably elevated in response to acute laser-induced injury of the retina. We used a global proteomics approach to analyze serum, along with a stringent data filtering method, to detect and identify the proteins most consistently elevated following laser treatment. Liquid chromatography/tandem mass spectrometry-based shotgun proteomics is a highly sensitive technique to detect alterations in the proteome of diseased tissue or body fluid. Proteomic analysis of complex mixtures, such as serum, can be challenging in terms of the sensitivity of detection. Therefore, we employed pre-fractionation of serum by isoelectric focusing to increase detectability of potentially low abundant protein candidates. Label-free quantitative proteomics is based on the assumption that increased abundance of a specific protein will lead to increased spectral counts of its tryptic peptides identified by LC/MS/MS. The resultant observable indices include chromatographic ion peak intensity, sequence coverage, peptide number, and spectral count [26]. We used the spectral counting approach for the relative quantification of proteins in serum. Comparison of the total number of MS/MS spectra detected for a given protein (spectral counting) is a reliable and highly reproducible method for relative quantitation. In fact, it has been demonstrated that spectral count is the factor with the strongest correlation ($r^2=0.9997$) to protein abundance [27]. We used the G statistic to assess significant differences and then applied a post-hoc Holm-Sidak adjustment of the $p$ value to correct for multiple testing. The G-test was found to be the most appropriate method of statistical analysis based upon our experimental design [24,28]. We applied additional layers of stringency to the data filtering process to minimize false identifications, to identify proteins that were significantly upregulated following laser injury, and to increase our confidence in the final protein biomarker candidate list.

Since the retinal damage was localized to the RPE photoreceptor complex, we expected that photoreceptor- and RPE-specific proteins would be detected in the serum. For this to be the case, one presumes these proteins survive the laser assault intact, are shed from cells, and pass into the circulation system in detectable amounts. Our inability to detect any

![Figure 2](http://www.molvis.org/molvis/v17/a88)
| Protein description                         | Biological process GO term                                      | Cellular component GO term                  |
|-------------------------------------------|----------------------------------------------------------------|--------------------------------------------|
| Alpha-1D adrenoceptor (ADRA1D)             | GO:0007165-Signal transduction                                  | GO:0016021-Integral to membrane            |
| Beta-1 adrenergic receptor (ADRB1)         | GO:0007165-Signal transduction                                  | GO:0016021-Integral to membrane            |
| Ephrin receptor A2 (EPHA2)                  | GO:0007165-Signal transduction                                  | GO:0016021-Integral to membrane            |
| Taste receptor type 2 (TAS2R5)              | GO:0007165-Signal transduction                                  | GO:0016021-Integral to membrane            |
| Nicotinic receptor alpha 5 subunit (CHRNA5) | GO:0007165-Signal transduction                                  | GO:0016021-Integral to membrane            |
| Alpha-1A adrenoceptor (ADRA1A)              | GO:0007165-Signal transduction                                  | GO:0016021-Integral to membrane            |
| Toll-like receptor 8 (TLR8)                 | GO:0007165-Signal transduction                                  | GO:0016021-Integral to membrane            |
| MHC class I antigen (HLA-B)                 | GO:0006955-Immune response                                     | GO:0016021-Integral to membrane            |
| Lewis alpha-3-fucosyltransferase (FUT3)     | GO:0006955-Immune response                                     | GO:0016021-Integral to membrane            |
| Cytochrome P450, 3A43 (CYP3A43)             | GO:0055114-Oxidation reduction                                  | GO:0031090-Organelle membrane              |
| Phosphoglycerate kinase 1 (PGK1)            | GO:0043687-Post-translational protein modification              | GO:0031090-Organelle membrane              |
| Cereblon (CRBN)                             | GO:0043687-Post-translational protein modification              | GO:0031090-Organelle membrane              |
| Tyrosine kinase-2 (TYK2)                    | GO:0043687-Post-translational protein modification              | GO:0031090-Organelle membrane              |
| Keratin 18 (CK18)                           | GO:0043687-Post-translational protein modification              | GO:0031090-Organelle membrane              |
| 28kDa calbindin 1 (CALB1)                   | GO:0006915-Apoptosis                                            | GO:0005737-Cytoplasm                       |
| Protein phosphatase 1, regulatory subunit 10 (PPP1R10) | GO:0048167-Regulation of synaptic plasticity                  | GO:0005737-Cytoplasm                       |
| C-C motif chemokine 5 (CCL5)                | GO:0006350-Transcription                                       | GO:0005634-Nucleus                         |
| Complement factor 4 (C4)                   | GO:0006954-Inflammatory response                                | GO:0005576-Extracellular region            |
| Tissue factor pathway inhibitor (TFPI)       | GO:0006954-Inflammatory response                                | GO:0005576-Extracellular region            |
|                                          | GO:00067596-Blood coagulation                                   | GO:0005576-Extracellular region            |
The candidate protein biomarkers identified in this study represent a wide array of proteins that were elevated to significant levels in the serum during the early phases following injury, but that appeared to rapidly return to basal levels. These proteins may have been upregulated locally in the retina at the site of injury and may have entered the systemic circulation through a compromised blood-retina barrier (BRB). Retinal laser injury could lead to induction of pathways for response to ischemia, inflammation, or cell death [8,9]. Events such as these, resulting in protein upregulation, might explain the presence of detectable levels in serum. Gene ontology analysis revealed four proteins with common biologic processes that are known to participate in immune responses. Two of these proteins, C-C motif chemokine 5 (CCL5) and Complement factor 4 (C4), are more specifically classified as inflammatory response proteins. C-C motif chemokine 5 is expressed in the RPE and may have a role in the migration of inflammatory cells across the BRB [29,30]. Increased expression of CCL5 has been associated with autoimmune uveitis [31,32] and has been shown to be a potential serum marker of diabetic retinopathy [33]. The idea that chemokine production at the BRB may increase in response to retinal injury, controlling infiltration of immune cells, and may be detectable at the systemic level, is of particular interest and requires further investigation. We also observed that the temporal profile of the biomarker response may correspond to both the gene expression changes shown to occur following retinal injury [34] and the initial tissue changes after laser injury reported by Tso et al. [5,7,35]. Photoreceptor mummification and RPE necrosis from thermal damage, ischemia resulting from damage to the choriocapillaris, and disruption of the outer BRB, all histologically observed at 1 day post-injury, coincides with our observation of maximum protein biomarker elevation in serum. This type of early response is similar to that described following traumatic brain injury (TBI) or during ischemic events in the brain, where a rapid and transient upregulation of proteins marks the acute-phase reaction [36-38]. The most successful surrogate marker of TBI, protein S-100B, when measured in serum has been shown to be useful in assessing injury severity [39] and as a reliable indicator of blood-brain barrier disruption [40].

Four proteins in our analysis were significantly elevated at both the 4 h and 1 day time points when compared to the serum from controls and the protein levels returned to baseline after 3 days. The proteins included CK18, PGK1, FUT3, and EPHA2. At 4 h following injury, these proteins were detected as being significantly elevated in the serum and then showed a trend toward further elevation after 1 day, suggesting a continuous release of proteins with changes in the biomarker profile for up to 24 h following laser treatment. Although other proteins that showed significant change at only one time point may indeed be of importance, the changes seen with CK18, PGK1, FUT3, and EPHA2 are most apparent and are therefore discussed in detail below.

CK18 is one of the four proteins that showed a transient significant increase in the serum following retinal laser injury. The protein, a component of the cytoskeleton belonging to the intermediate filament family of proteins, is expressed mainly in epithelial cells [41]. In the retina, CK18 expression is restricted to the RPE and is the dominant cytokeratin type in those cells [42-44]. This specificity makes CK18 an effective marker for RPE cell identification [42]. It has been shown that cleavage of CK18 by caspases is an early apoptotic event [45]. Numerous reports suggest that caspase cleaved fragments of CK18, because they can be detected in serum, are a useful indicator of epithelial cell death [46-48]. Our data showed significant detection of CK18 peptides in the serum of laser-treated animals. The peptides detected were tryptic peptides corresponding to a region within the caspase cleaved CK18 fragment (data not shown). We suspect that acute damage of RPE cells induced either a necrotic or apoptotic mode of cell death and that the resulting CK18 fragments are detectable upon release into the serum. Additional studies of the laser dose response and other variables are needed to determine the detection thresholds for such a biomarker in the serum.

PGK1 is an ubiquitous glycolytic enzyme that catalyzes the conversion of 1,3-diphosphoglycerate to 3-phosphoglycerate [49]. In the retina, PGK1 appears to be upregulated in maturing photoreceptors [50] and PGK1 deficiency has been implicated in one case of retinitis pigmentosa [51]. It is likely this enzyme is abundant in metabolically active tissue, such as the retina, and may be the source of the PGK1 seen in the serum after laser injury. PGK1 is upregulated in response to hypoxia [52,53] and during hypoxia-induced apoptosis in cultured retinal neurons [54]. It is therefore feasible that upregulation of PGK1 in the retina might have occurred in the area surrounding the laser injury. It remains unclear whether such an increase in expression would contribute to elevated PGK1 serum levels within 4 h and 1 day after laser exposure, but it is likely released as a direct result of tissue damage in the retina.

EPHA2 belongs to a subfamily of receptor protein-tyrosine kinases. Studies have shown it is expressed mainly in the retinal ganglion cells, but also in amacrine cells and the outer retina during development [55,56]. It plays a role in the development of the retinotectal projection system and is also expressed in the adult retina [55-57]. Following retinal laser injury, altered expression is observed for both ephrin A2 in
the superior colliculus and EPHA5 in the retina [58]. Our observation of increased levels of EPHA2 in the serum following retinal laser injury, affecting mainly the outer retina, is somewhat unexpected. It is possible that some injury may have occurred to amacrine cells following the laser injury, which was not clearly evident during our histological assessment of one animal. Also, since EPHA2 is upregulated in the region of growth cones, laser injury may stimulate its production in the outer retina. It is possible that elevated levels of EPHA2 in the inner retina diffuse through a disrupted BRB in response to injury and enter the systemic circulation, allowing detection in the serum. Further studies of the retinal expression of ephrin receptor A2 and additional validation is needed before any definite conclusions can be made regarding this finding.

FUT3 is the enzyme that catalyzes the addition of fucose to precursor polysaccharides in the last step of Lewis antigen biosynthesis [59]. The Lewis histo-blood group system comprises a set of fucosylated glycosphingolipids that are synthesized by exocrine epithelial cells and that circulate in body fluids. Additionally, these glycosphingolipids function in embryogenesis, tissue differentiation, tumor metastasis, inflammation, and cell adhesion [60-62]. Evidence exists for increased FUT3 activity and the resultant increased abundance of Lewis antigen-bearing glycolipids during hepatic inflammation [63], neural differentiation [64], and in epithelial cancer cells [60,65]. It is also known that these fucosylated glycolipids are ligands for E-selectin receptors [66]. Because E-selectin is expressed in retinal vascular endothelial cells and has a role in recruiting inflammatory cells across the BRB [67], it is possible that increased expression and activity of the fucosyltransferases might occur at a retinal injury site. This connection between E-selectin and fucosyltransferases could be relevant to our case of retinal injury if RPE cells do in fact express FUT3. Although the preferential expression of FUT3 in epithelia is known, no sources discuss its activity in the RPE. It would therefore be necessary to assess the presence of FUT3 in RPE and identify an increased expression following retinal injury. The reason for elevation of this enzyme in the sera following retinal injury remains unclear. One could suggest that this response is either related to early-phase inflammatory processes or as a result of FUT3 upregulation followed by release from laser-damaged RPE cells. Further investigation into this response is warranted.

This study is unique in that there are no comparator studies of a similar nature that address acute retinal injury. Most reported studies have used proteomic techniques to investigate alterations in the retinal proteome as a result of diabetes, age-related macular degeneration, or glaucoma. Some studies have assessed the proteomes of intraocular fluids, such as the aqueous humor, and were able to demonstrate significant alterations at the tissue level. However, few studies have been able to demonstrate potential biomarkers of ocular disease in serum and there are none, to our knowledge, relating to acute injury. Great difficulty is typically encountered when attempting to detect potentially low abundance proteins in a complex biologic fluid such as serum. Our ability to identify protein biomarker candidates was perhaps limited by the very nature of using a shotgun proteomics technique. These intrinsic limitations include threshold of detection, under sampling, and sample complexity [68]. Although we employed a strategy of serial fractionation to increase the protein identification rate, the possibility exists that retina-specific proteins may have been present in the serum but were missed due to any of these limitations. We also considered whether the biomarker response we observed was specific to retinal laser injury or if a similar response could occur following laser injury of other structures, such as the trabecular meshwork or iris. Experiments to address this question would be difficult to design. Attempts to replicate laser injury in other tissues with effects that mimic those seen in the retina could be inconsistent, especially if trying to control for laser energy levels and number of spots. Additionally, laser-tissue interactions in the retina and the observed effects are different from those elicited in other ocular tissues. This suggests that the response, although yet to be determined, may be different. Despite these limitations, the technique has proven useful for comparative global protein profiling of serum and we were able to identify biomarker candidates that may be significantly indicative of acute retinal injury. Further investigation focusing on individual candidate proteins is necessary.

ACKNOWLEDGMENTS
This work was supported by USAF SGR contract #FA7014–07-C-A012. The authors declare no commercial relationships associated with the submitted work.

REFERENCES
1. Dunker S, Sadun AA, Sebag J. Neuron specific enolase in retinal detachment. Curr Eye Res 2001; 23:382-5. [PMID: 11910528]
2. Kim K, Kim SJ, Yu HG, Yu J, Park KS, Jang IJ, Kim Y. Verification of biomarkers for diabetic retinopathy by multiple reaction monitoring. J Proteome Res **; 9:689-99. [PMID: 20020744]
3. Marshall J. Thermal and mechanical mechanisms in laser damage to the retina. Invest Ophthalmol 1970; 9:97-115. [PMID: 5415018]
4. Peyman GA, Raichand M, Zeimer RC. Ocular effects of various laser wavelengths. Surv Ophthalmol 1984; 28:391-404. [PMID: 6426070]
5. Wallow IH, Tso MO. Repair after xenon arc photocoagulation. 2. A clinical and light microscopic study of the evolution of retinal lesions in the rhesus monkey. Am J Ophthalmol 1973; 75:610-26. [PMID: 4633188]
6. Pollack JS, Kim JE, Pulido JS, Burke JM. Tissue effects of subclinical diode laser treatment of the retina. Arch Ophthalmol 1998; 116:1633-9. [PMID: 9869794]
7. Wallow IH, Tso MO, Fine BS. Retinal repair after experimental xenon arc photocoagulation. I. A comparison between rhesus monkey and rabbit. Am J Ophthalmol 1973; 75:32-52. [PMID: 4630711]

8. Tackenberg MA, Tucker BA, Swift JS, Jiang C, Redenti S, Greenberg KP, Flannery JG, Reichenbach A, Young MJ. Muller cell activation, proliferation and migration following laser injury. Mol Vis 2009; 15:1886-96. [PMID: 19768129]

9. Wilson AS, Hobbs BG, Shen WY, Speed TP, Schmidt U, Begley CG, Rakoczy PE. Argon laser photocoagulation-induced modification of gene expression in the retina. Invest Ophthalmol Vis Sci 2003; 44:1426-34. [PMID: 12657576]

10. Pollack A, Korte GE. Restoration of the outer blood-retinal barrier after krypton laser photocoagulation. Ophthalmic Res 1993; 25:201-9. [PMID: 8233344]

11. Sato Y, Berkowitz BA, Wilson CA, de Juan E Jr. Blood-retinal barrier breakdown caused by diode vs argon laser endophotocoagulation. Arch Ophthalmol 1992; 110:277-81. [PMID: 1736878]

12. Shiga S, Hayashi H, Oshima K. Immunohistochemical localization of blood-retinal barrier breakdown after argon laser photocoagulation in the monkey retina. Nippon Ganka Gakkai Zassi 1994; 98:463-8. [PMID: 8197916]

13. Hollyfield JG, Salomon RG, Crabb JW. Proteomic approaches to understanding age-related macular degeneration. Adv Exp Med Biol 2003; 533:83-9. [PMID: 15180251]

14. Marshall J, Hamilton AM, Bird AC. Histopathology of ruby and argon laser lesions in monkey and human retina. A comparative study. Br J Ophthalmol 1975; 59:610-30. [PMID: 812546]

15. Anderson NL, Anderson NG. The human plasma proteome: history, character, and diagnostic prospects. Mol Cell Proteomics 2002; 1:845-67. [PMID: 12488461]

16. Guerrier L, Lomas L, Boschetti E. A simplified monobuffer multidimensional chromatography for high-throughput proteome fractionation. J Chromatogr A 2005; 1073:25-33. [PMID: 15909502]

17. Li X, Gong Y, Wang Y, Wu S, Cai Y, He P, Lu Z, Ying W, Zhang Y, Jiao L, Zhang H, Zhang Z, He F, Zhao X, Qian X. Comparison of alternative analytical techniques for the characterisation of the human serum proteome in HUPO Plasma Proteome Project. Proteomics 2005; 5:3423-41. [PMID: 16052619]

18. Tirumalai RS, Chan KC, Prieto DA, Issaq HJ, Conrads TP, Veenstra TD. Characterization of the low molecular weight human serum proteome. Mol Cell Proteomics 2003; 2:1096-103. [PMID: 12917320]

19. Bellii E, Bergamini S, Mancini L, Fantoni LI, Cuoghi A, Ozben T, Tomasi A. High-abundance proteins depletion for serum proteome analysis: concomitant removal of non-targeted proteins. Amino Acids 2011; 40:145-56. [PMID: 20495836]

20. Stempfer R, Kubicek M, Lang IM, Christa N, Gerner C. Quantitative assessment of human serum high-abundance protein depletion. Electrophoresis 2008; 29:4316-23. [PMID: 18956433]

21. Yu H, Wakim B, Li M, Halligan B, Tint GS, Patel SB. Quantifying raft proteins in neonatal mouse brain by ‘tube-gel’ protein digestion label-free shotgun proteomics. Proteome Sci 2007; 5:17. [PMID: 17892558]

22. Mesrobian HG, Mitchell ME, See WA, Halligan BD, Carlson BE, Greene AS, Wakim BT. Candidate urinary biomarker discovery in ureteropelvic junction obstruction: a proteomic approach. J Urol 2010; 184:709-14. [PMID: 20639044]

23. Sharma M, Halligan BD, Wakim BT, Savin VJ, Cohen EP, Moulder JE. The Urine Proteome as a Biomarker of Radiation Injury: Submitted to Proteomics- Clinical Applications Special Issue: “Renal and Urinary Proteomics” (Thongboonkerd). Proteomics Clin Appl 2008; 2:1065-86. [PMID: 19746194]

24. Hendrickson EL, Xia Q, Wang T, Leigh JA, Hackett M. Comparison of spectral counting and metabolic stable isotope labeling for use with quantitative microbial proteomics. Analyst (Lond) 2006; 131:1335-41.

25. Bouhenni RA, Al Shashwan S, Morales J, Wakim BT, Chomik AM, Alkuraya FS, Edward DP. Identification of differentially expressed proteins in the aqueous humor of primary congenital glaucoma. Exp Eye Res 2011; 92:67-75. [PMID: 21078314]

26. Washburn MP, Wolters D, Yates JR 3rd. Large-scale analysis of the yeast proteome by multidimensional protein identification technology. Nat Biotechnol 2001; 19:242-7. [PMID: 11231557]

27. Liu H, Sadygov RG, Yates JR 3rd. A model for random sampling and estimation of relative protein abundance in shotgun proteomics. Anal Chem 2004; 76:193-201. [PMID: 15253663]

28. Zhang B, VerBerkmoes NC, Langston MA, Uberbacher E, Hettich RL, Samatova NF. Detecting differential and correlated protein expression in label-free shotgun proteomics. J Proteome Res 2006; 5:2909-18. [PMID: 17081042]

29. Crane IJ, Kuppner MC, McKillop-Smith S, Knott RM, Forrester JV. Cytokine regulation of RANTES production by human retinal pigment epithelial cells. Cell Immunol 1998; 184:37-44. [PMID: 9626333]

30. Crane IJ, Wallace CA, McKillop-Smith S, Forrester JV. Control of chemokine production at the blood-retina barrier. Immunology 2000; 101:426-33. [PMID: 11106948]

31. Crane IJ, McKillop-Smith S, Wallace CA, Lamont GR, Forrester JV. Expression of the chemokines MIP-1 alpha, MCP-1, and RANTES in experimental autoimmune uveitis. Invest Ophthalmol Vis Sci 2001; 42:1547-52. [PMID: 11381059]

32. Sonoda KH, Sasa Y, Qiao H, Tsutsumi C, Komiyama S, Kubota T, Sakamoto T, Kawano Y, Ishibashi T. Immunoregulatory role of ocular macrophages; the macrophages produce RANTES to suppress experimental autoimmune uveitis. J Immunol 2003; 171:2652-9. [PMID: 12928419]

33. Meleth AD, Agron E, Chan CC, Reed GF, Arora K, Byrne G, Csaky KG, Ferris FL 3rd, Chew EY. Serum inflammatory markers in diabetic retinopathy. Invest Ophthalmol Vis Sci 2005; 46:4295-301. [PMID: 16249511]

34. Vázquez-Chona F, Song BK, Geisert EE Jr. Temporal changes in gene expression after injury in the rat retina. Invest Ophthalmol Vis Sci 2004; 45:2737-46. [PMID: 15277499]

35. Tso MO, Wallow IH, Elgin S. Experimental photocoagulation of the human retina. I. Correlation of physical, clinical, and
pathologic data. Arch Ophthalmol 1977; 95:1035-40. [PMID: 869746]

36. Herrmann M, Vos P, Wunderlich MT, de Bruijn CH, Lamers KJ. Release of glial tissue-specific proteins after acute stroke: A comparative analysis of serum concentrations of protein S-100B and glial fibrillary acidic protein. Stroke 2000; 31:2670-7. [PMID: 11062293]

37. Romner B, Ingebrigtsen T, Kongstad P, Borgesen SE. Traumatic brain damage: serum S-100 protein measurements related to neuroradiological findings. J Neurotrauma 2000; 17:641-7. [PMID: 10972241]

38. Dassan P, Keir G, Brown MM. Criteria for a clinically informative serum biomarker in acute ischaemic stroke: a review of S100B. Cerebrovasc Dis 2009; 27:295-302. [PMID: 19202335]

39. Castellani C, Bimbashi P, Ruttenstock E, Sacherer P, Stojakovic T, Weinberg AM. Neuropeptide s-100B—a useful parameter in paediatric patients with mild traumatic brain injury? Acta Paediatr 2009; 98:1607-12. [PMID: 19843102]

40. Blyth BJ, Farhavar A, Gee C, Hawthorn B, He H, Nayak A, Stöcklein V, Bazarian JJ. Validation of serum markers for blood-brain barrier disruption in traumatic brain injury. J Neurotrauma 2009; 26:1497-507. [PMID: 19257803]

41. Moll R, Franke WW, Schiller DL, Geiger B, Krepler R. The cytoskeleton in normal and tumoral human retinal pigment epithelial cells: in vitro and in vivo. J Cell Sci 1988; 91:303-12. [PMID: 2457569]

42. Fuchs U, Kivela T, Tarkkanen A. Cytoskeleton in normal and reactive human retinal pigment epithelial cells. Invest Ophthalmol Vis Sci 1991; 32:3178-86. [PMID: 1748549]

43. Kasper M, Moll R, Stosiek P, Karsten U. Patterns of cytokeratin and vimentin expression in the human eye. Histochemistry 1988; 89:369-77. [PMID: 2457569]

44. Brandt D, Volkmann X, Anstätt M, Länger F, Manns MP, Schulze-Osthoff K, Bantel H. Serum biomarkers of cell death and vimentin expression in the human eye. Histochemistry 1988; 89:369-77. [PMID: 2457569]

45. Goldshmit Y, McLenachan S, Turnley A. Roles of Eph receptors and ephrins in the normal and damaged adult CNS. Brain Res Brain Res Rev 2006; 52:327-45.

46. Rodger J, Symonds AC, Springbett J, Shen WY, Bartlett CA, Rakoczy PE, Beazley LD, Dunlop SA. Eph/ephrin expression in the adult rat visual system following localized retinal lesions: localized and transneuronal up-regulation in the retina and superior colliculus. Eur J Neurosci 2000; 12:3626-36. [PMID: 11029633]

47. Xu L, Ma J, Seigel GM, Ma JX. l-Deprenyl, blocking apoptosis and regulating gene expression in cultured retinal neurons. Biochem Pharmacol 1999; 58:1183-90. [PMID: 10484076]

48. Ng Y, Li J, Shu J, Zhang H, Huang J, Cai Z, Su Y, Wang Z, Wang Y, Hu X, Sun H. The expression of HIF1alpha gene in human glioma cell lines under hypoxia. J Biol Chem 2009; 284:22588-96. [PMID: 19208827]

49. Yoshida A. Human phosphoglycerate kinase. Methods Enzymol 1975; 42:144-8. [PMID: 1134351]

50. Tummala P, Mali RS, Guzman E, Zhang X, Mitton KP. Temporal ChIP-on-Chip of RNA-Polymerase-II to detect novel gene activation events during photoreceptor maturation. Mol Vis 2010; 16:252-71. [PMID: 20161818]

51. Tonin P, Shanske S, Miranda AF, Brownell AK, Wyse JP, Tsujino S, DiMauro S. Phosphoglycerate kinase deficiency: biochemical and molecular genetic studies in a new myopathic variant (PGK Alberta). Neurology 1993; 43:387-91. [PMID: 7679780]

52. Lam W, Bussom S, Cheng YC. Effect of hypoxia on the expression of phosphoglycerate kinase and antitumor activity of troxacitabine and gemcitabine in non-small cell lung carcinoma. Mol Cancer Ther 2009; 8:415-23. [PMID: 19208827]

53. Li H, Ko HP, Whitlock JP. Induction of phosphoglycerate kinase 1 gene expression by hypoxia. Roles of Arnt and HIF1alpha. J Biol Chem 1996; 271:21262-7. [PMID: 8702901]

54. Xu L, Ma J, Seigel GM, Ma JX. l-Deprenyl, blocking apoptosis and regulat
64. Osanai T, Chai W, Tajima Y, Shimoda Y, Sanai Y, Yuen CT. Expression of glycoconjugates bearing the Lewis X epitope during neural differentiation of P19 EC cells. FEBS Lett 2001; 488:23-8. [PMID: 11163789]

65. Yago K, Zenita K, Ginya H, Sawada M, Ohmori K, Okuma M, Kannagi R, Lowe JB. Expression of alpha-(1,3)-fucosyltransferases which synthesize sialyl Le(x) and sialyl Le(a), the carbohydrate ligands for E- and P-selectins, in human malignant cell lines. Cancer Res 1993; 53:5559-65. [PMID: 7693344]

66. Lasky LA. Selectins: interpreters of cell-specific carbohydrate information during inflammation. Science 1992; 258:964-9. [PMID: 1439808]

67. Crane IJ, Liversidge J. Mechanisms of leukocyte migration across the blood-retina barrier. Semin Immunopathol 2008; 30:165-77. [PMID: 18305941]

68. Malmström J, Lee H, Aebersold R. Advances in proteomic workflows for systems biology. Curr Opin Biotechnol 2007; 18:378-84. [PMID: 17698335]

69. Tso MO, Wallow IH, Elgin S. Experimental photocoagulation of the human retina. I. Correlation of physical, clinical, and pathologic data. Arch Ophthalmol 1977; 95:1035-40. [PMID: 869746]

70. Toth CA, Birngruber R, Boppart SA, Hee MR, Fujimoto JG, DiCarlo CD, Swanson EA, Cain CP, Narayan DG, Noojin GD, Roach WP. Argon laser retinal lesions evaluated in vivo by optical coherence tomography. Am J Ophthalmol 1997; 123:188-98. [PMID: 9186124]
Appendix 1. Comprehensive lists of identified proteins, significantly detected by 2 or more non-redundant peptides, before data filtering.

To access the data, click or select the words “Appendix 1.” This will initiate the download of a compressed (pdf) archive that contains the file.